Molecular Matrix, Inc. (“MMI”), a California company incorporated in August 2011, has been developing an innovative bone regeneration product based on a novel hyper-crosslinked carbohydrate polymer (HCCP) technology. MMI received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Osteo-PTM Bone Graft Substitute (Osteo-PTM BGS), manufactured using the HCCP technology. MMI expects to enter the orthopedic market in Q3 2018. The global bone graft and substitutes market is expected to grow to $3.6 billion by 2024 with an estimated CAGR of 5.2% from 2016. Currently, off-the-shelf bone substitute products (e.g., demineralized bone matrix, hydroxyapatite) are available for various bone conditions. These products have multiple inherent disadvantages associated with their use such as disease transmission, insufficient bone formation, poor absorption over time, inability to evaluate bone formation real-time, inability to be used as an efficient carrier of biologics or molecules, and high cost of utilization. MMI is uniquely poised to eliminate these problems using the platform HCCP technology and enter the market with a safe, clinically effective, and inexpensive orthopedic solution that is rapidly replaced by new bone formed in patients.